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Introduction 
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 INTRODUCTION 
Multiple myeloma is a clonal plasma cell disorder that varies widely in its 
clinical course ranging from relatively indolent forms to frankly aggressive 
neoplasia [1]. The clinical manifestations of this disorder result from the 
proliferation and accumulation of these neoplastic cells and, the effect of 
marrow replacement by them. The pathologic manifestations are due to over 
production of certain proteins and constituent polypeptide chains. Bone 
marrow examination continues to be the cornerstone for establishing a 
diagnosis in association with other clinical and laboratory parameters [2]. 
Several clinical, laboratory  and morphological variables help us in 
determining the prognosis of the disease. The first histological classification 
and staging of myeloma was put forth by Bartl et al in 1987[2]. Multiple 
myeloma has been classified into 6 histological types: 
· Marschalko type 
· Small cell type 
· Cleaved type 
· Polymorphous type 
· Asynchronous type 
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· Blastic type 
These six types were subsequently combined into 3 prognostic grades 
· Low grade 
· Intermediate grade 
· High grade 
Histological parameters that have a definitive prognostic significance in 
multiple myeloma are the percentage of myeloma cells in the marrow, 
pattern of infiltration, plasma cell atypia, marrow fibrosis & mitotic index[3]. 
The quantity of plasma cell burden in the biopsy has proved to be a very 
useful criterion for histological staging of multiple myeloma, supplementing 
any clinical staging system. Both these parameters, grade and stage provide 
information required for decisions on treatment modalities, while the effects 
of therapy can be monitored by sequential biopsies.  
Classical cases of myeloma are composed of easily recognizable plasma 
cells and can be diagnosed without any difficulty.[4] Some cases may pose a 
considerable diagnostic problem as they exhibit unusual cytological  
features. This cytological aberration if unrecognized leads to an erroneous 
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diagnosis.[5] This study aims at analyzing the morphological variants of 
plasma cells in multiple myeloma. 
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  AIMS AND OBJECTIVES 
1. To analyze the occurrence of multiple myeloma in the bone marrow 
aspirate smears received between January 2005 to October 2011 
2. To examine the bone marrow aspirate smears and perform a 
morphological grading of plasma cells  
3. To analyze the percentage of myeloma cells in the marrow on aspirate 
smears 
4. To review the bone marrow trephine biopsies using Bartl’s 
histological grading system 
5. To study the growth pattern and tumour cell burden in bone marrow 
biopsies 
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MATERIALS AND METHODS 
Patients who were clinically diagnosed as multiple myeloma in PSG OPD 
for whom bone marrow (BM) aspirate and trephine biopsy were done 
between January 2005 and October 2011, were included in the study. 
 SAMPLE COLLECTION: 
After clinical evaluation, bone marrow aspirate and trephine biopsy were 
obtained for all patients. The trephine biopsy specimen was fixed in  B5 
solution for routine histopathological examination and the aspirate was 
smeared without any delay as the bone marrow clots faster than the 
peripheral blood. 
MATERIALS REQUIRED FOR COLLECTION OF SPECIMEN: 
· 70% alcohol or spirit swab for cleaning the skin 
· Local anaesthetic agent – 2% xylocaine 
· BM aspirate needle for obtaining  BM sample 
· Jamshidi needle for obtaining BM trephine biopsy 
· Clean glass slides 
· Methanol – fixative agent 
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· B5 Solution – fixative agent 
BONE MARROW ASPIRATION PROCEDURE:  
Satisfactory BM sample was generally aspirated from the sternum, iliac 
crest, anterior or posterior iliac spines. Both BM aspirate and trephine 
biopsy were obtained at a single sitting under local anaesthesia. 
To perform marrow aspiration, the skin was cleaned with 70% alcohol and  
the skin, subcutis and overlying periosteum were infiltrated  with  local 
anaesthetic (2 – 5ml of 2% xylocaine). With a boring movement, the needle 
was introduced perpendicularly into the the ileum at the posterior superior 
iliac spine. After penetrating the bone, the stillete was removed and a 10 ml 
syringe was fixed to the needle to aspirate the marrow contents for making 
films. 
The films were made without any delay. The films were made for a length 
of 3 – 5 cm from the aspirated marrow contents using a smooth edged glass 
spreader.  
GIEMSA STAINING: 
MATERIALS REQUIRED: 
· Absolute methanol 
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· Giemsa stain [ 1 volume of stain with two volumes of distilled water] 
· Mounting medium 
STAINING PROCEDURE: 
1. The slides were dried thoroughly. Fixation is for 20 minutes with 
absolute methanol 
2. The slides were next exposed to Giemsa stain solution for 30 minutes 
3. The stain was flushed with water 
4. The back of the slides were cleaned with gauze and were allowed to 
air dry in a tilted position 
5. The slides were mounted and labeled appropriately 
EVALUATION OF BONE MARROW ASPIRATE SMEARS: 
The smears were examined under scanner, low power, high power and oil 
immersion objectives. The preparation was considered satisfactory only 
when marrow particles and free marrow cells were observed in the stained 
films. A 500 cell differential count was performed in the cellular trails. In 
addition to the assessment  of cellularity, evaluation of nature of 
erythropoiesis, assessment of myeloid series, the M/ E ratio, an estimate of 
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the number of megakaryocytes, any cytological or maturational 
abnormalities , the percentage of plasma cells in the aspirate was also 
estimated. All counted plasma cells were also subjected to morphological 
analysis.  
BM TREPHINE BIOPSY PROCEDURE: 
The trephine specimen was obtained from bone by using the Jamshidi 
needle. The needle was rotated to and fro to obtain a core of tissue. The 
specimen in B5 solution was transferred into 10% formalin after 2 – 4 hrs of 
B5 fixation. It was then decalcified in acid decalcifying agent (nitric acid 10 
ml +distilled water 100 ml) and processed in an automated tissue processing 
unit before being embedded in paraffin. The sections were stained using 
routine hematoxylin and eosin, mounted and labeled. 
HEMATOXYLIN AND EOSIN STAINING: 
MATERIALS REQUIRED: 
· Harris hematoxylin 
· 1% eosin Y 
· Xylene 
· 1% acid alcohol 
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· Graded alcohol 
STAINING PROCEDURE: 
1. The sections were deparaffinized and hydrated through graded 
alcohols to water 
2. Stained in Harris hematoxylin for 5 minutes 
3. Washed well in running tap water until sections were blue for 5 
minutes 
4. Differentiated in 1% acid alcohol (1% hydrochloric acid in 70% 
alcohol) for 5 – 10 seconds 
5. Washed well in tap water until sections were again blue (10 – 15 min) 
6. Stained in 1% eosin Y for 2 minutes 
7. Washed in running tap water for 1- 5 minutes 
8. Dehydrated through alcohols, cleared in Xylene and mounted. 
EVALUATION OF BONE MARROW BIOPSY SECTIONS: 
Trephine biopsy was referred to as adequate if the trephine had at least 3 
marrow spaces below the sub-cortical space. The biopsies were evaluated 
for cellularity, hematopoietic elements, volume and pattern of plasma cell 
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infiltration and degree of fibrosis. A morphological grading was done based 
on the criteria proposed by Bartl et al. In those cases where fibrosis was 
suspected a reticulin staining was performed. 
GOMORI’S METHOD FOR RETICULIN STAINING: 
MATERIALS REQUIRED: 
· 0.5 % Potassium permanganate 
Potassium permanganate – 0.5 gm 
Distilled water – 100 ml 
· 2% oxalic acid 
Oxalic acid  - 2.0 gm  
Distilled water  - 100ml 
· 2% ferric ammonium sulphate 
Ferric ammonium sulphate 2.0 gm 
Distilled water – 100 ml 
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· 10% Silver nitrate solution 
2.5 ml of 105 aqueous solution of KOH was added to 10 ml of 10% 
silver nitrate solution and mixed well. 28% ammonia was added drop 
by drop until the precipitate was completely dissolved. 4 drops of 
silver nitrate was added again. The solution was made twice its 
volume by adding more distilled water. 
· 20% formalin 
40% formalin -  20 ml 
Distilled water 100ml 
PROCEDURE: 
1. The sections were deparaffinized and brought to water 
2. Treated with potassium permanganate solution for 1 minute 
3. Washed with distilled water 
4. Bleached in 2% oxalic acid solution for 1 minute 
5. Washed in distilled water 
6. Treated with 2% ferric ammonium sulphate for 1 minute  
7. Washed in distilled water 
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8. Placed in a coplin jar of silver solution for 1 minute 
9.  Washed in distilled water 
10. Reduced in 20% formalin for 1 minute 
11. Rinsed in tap water 
12. Dehydrated through graded alcohol, cleared in Xylene and mounted 
GRADING OF FIBROSIS IS DONE AS FOLLOWS [6] 
GRADING DESCRIPTION 
0 No reticulin fibres seen 
1 Few scattered fine reticulin fibres  
2 Network of fine reticulin fibres in most of the sections.Coarse reticulin fibres are absent 
3 As  in [2],with coarse reticulin fibres. Collagen fibres absent 
4 Diffuse network of mainly coarse reticulin fibres.Collagen fibres present in some areas. 
     
  
 
 
 
 
 
 
 
 
 
Review of literature 
13 
 
REVIEW OF LITERATURE 
Multiple myeloma [plasma cell myeloma] is a differentiated B cell 
neoplasm characterized by skeletal dissemination of malignant plasma cells 
that produce monoclonal immunoglobulin [Ig] [7],[8]. Plasma cells are a 
crucial part of the immune system responsible for the production of 
antibodies in human beings. They are produced in the bone marrow and 
transported through the lymphatic system. Due to the fundamental nature of 
the system affected, multiple myeloma presents with heterogenous clinical 
features that makes it difficult to diagnose. 
Multiple myeloma (MM) is a debilitating disease which has been 
present for decades and has gained the interests of physicians and scientists. 
Cases of possible multiple myeloma have been reported in American Indian 
skeletons from 200 AD. In 1845, Dr. William Macintyre described the 
features of myeloma in a patient named, Mc Bean. Macintyre and Bence 
Jones examined and described the properties of urine in that patient. Bence 
Jones estimated that   67gm of proteins / day was excreted by the patient and 
he concluded that the protein was ‘hydrated deuteroxide of albumin’. 
Henceforth, the name Bence Jones protein came into existence. 
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In 1873, a Russian doctor, Dr.Von Rustizky performed an autopsy 
and found 8 separate tumors of the bone marrow which he designated as 
multiple myeloma [9],[10]. Hence, the term ‘Rustizky’s disease’ is often used 
for MM in Russia. However, he did not mention about albuminuria.  
Dr.Otto Kahler in 1885 noted one of the most striking cases of MM. 
The patient died two years later and the autopsy disclosed large round cells 
in the masses noted in the ribs and thoracic vertebra. Kahler recognized that 
the urinary protein had similar physical and chemical properties as 
described by Bence Jones. Dr.Otto Kahler reported this case in 1889 
following which much interest was generated in this disease. Hence MM is 
also known as Kahler’s disease named after him.  
 In 1956, Korngold and Lipari demonstrated a relationship between 
Bence Jones protein and serum proteins of MM. The designation of two 
major classes of Bence Jones proteins as Kappa and Lambda is a tribute to 
Korngold and Lipari [9],[10]. 
EPIDEMIOLOGY 
Plasma cell myeloma comprises about 1% of all malignant tumours 
[11],[12] and accounts for 10 % of hematopoietic neoplasms [9],[13],[14]. MM is 
more common in men than in women. The incidence of myeloma 
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progressively increases with age. The median age at diagnosis is 70 years 
[15],[16]. Occurrence of myeloma in patients less than 40 years is rare. MM 
occurs more frequently in Afro – Carribean ethnic groups compared with 
Caucasians [17]. 
ETIOLOGY OF MUTIPLE MYELOMA 
§ Atomic bomb exposure 
Reports of increased incidence of myeloma among Japanese atomic 
bomb survivors have suggested an association between ionizing 
radiation and multiple myeloma. 
§ Occupational exposure 
The risk of myeloma is considered to be two folds higher in 
radiologists than in physicians who are not exposed to radiation. 
Agricultural workers, workers in metal occupation and industries, 
exposure to benzene have been reported to have an increased 
myeloma risk 
§ Lifestyle factors 
Dietary links: Higher risk of myeloma was found among people 
consuming large quantities of liver and butter. Decreased risks were 
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associated with the intake of cruciferous vegetables, fish and vitamin 
C supplements 
Socio economic status: There exists an inverse relationship between 
the risk of multiple myeloma and socio economic status. 
Hair dyes: Women with prolonged usage of hair dyes are prone for 
developing non Hodgkin’s lymphoma and myeloma. 
§ Associated medical conditions: MGUS is a potential precursor for 
myeloma. The risk of progression is 1% per year[18],[19]. 
§ Chronic antigenic stimulation:  Myeloma is associated with chronic 
infections, inflammatory conditions, connective tissue disorders, auto 
immune illnesses, allergy related disorders and HIV. 
PATHOGENESIS 
Prolonged antigenic stimulations have been postulated in the 
pathogenesis of MM. A malignant stem cell in MM has not been identified, 
though phenotypic analysis has demonstrated involvement of early B 
lymphocytes circulating in the blood. These originate in the bone marrow, 
and / or in the lymphoid organs, circulate and seed in skeletal or extra 
skeletal sites. They use adhesion molecules to bind to the stromal elements 
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that provide the soil for their homing and maturation to mature plasma cells, 
which secrete a range of cytokines. Subsequent development and 
dissemination of MM is controlled by BM microenvironment which in turn 
is influenced by a battery of cytokines of which IL6 is the major myeloma 
factor. IL 6 appears to support the survival and expansion of myeloma cells 
by stimulating cell division and preventing programmed cell death.The net 
result of these cellular interactions determines growth and manifestations of 
MM. IL 6 along with IL 1 b and TNF alpha and other cytokines have 
osteoclastic activating properties and are responsible for lytic lesions 
involving the RANKL pathway [20],[21]. 
BONE MARROW MICROENVIRONMENT 
MM is primarily a bone marrow disorder in which malignant 
monoclonal B cells differentiate into plasma cells. The circulating malignant 
B cells require an optimal environment for survival and differentiation. The 
malignant monoclonal B cells differentiate into plasma cells by interaction 
with stromal cells, endothelial cells, extracellular matrix and other 
malignant plasma cells. Adhesion molecules play a role in the connection 
and interaction of these cells and components. Myeloma cells express 
specific receptors for IL 6. IL 6 is produced by the cells in the BM 
microenvironment. Other cytokines like VEGF, IGF 1, SDF 1 and TNF 
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alpha are also produced. These cytokines determine the growth 
differentiation and adhesion of the tumour cells. Syndecan 1 is another 
important adhesion molecule in the myeloma cell [22]. A high level of 
syndecan 1 in the serum is an indicator of poor prognosis [23] . 
CLINICAL MANIFESTATIONS 
MM is a well established clinical and immunological entity with 
considerable variability in biological behaviour and survival [2]. Majority of 
the myeloma patients are symptomatic at initial diagnosis presenting with 
bone pain [3], infections and anaemia [24] [25]. 
Bone pain usually involves the spine and ribs and worsens with 
activity. Persistent localized pain indicates a pathological bone fracture.  
Involvement of the vertebrae may lead to spinal cord compression. Bone 
lesions are lytic in nature and are best seen in plain radiographs, which 
shows punched out resorptive lesions (pepper pot appearance of the skull). 
Breakdown of bone can also lead to hypercalcemia. 
The most common infections are pneumonias and pyelonephritis. 
Common pneumonia pathogens include S.Pneumonia, S.Aureus and 
K.Pneumonia. Common pathogens causing pyelonephritis include E.Coli 
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and other gram negative organisms. Increased risk of infection is due to 
immune deficiency resulting from diffuse hypogamma globulinaemia. 
Renal failure may develop both acutely and chronically. It is 
commonly due to hypercalcemia but may also be due to Bence Jones protein 
excretion induced tubular damage. Other causes include glomerular 
deposition of amyloid, hyperuricaemia, recurrent infections and local 
infiltration of tumour cells. 
Anaemia in myeloma is directly related to the percentage of plasma 
cell infiltrate in the marrow. In fact, absence of anaemia is considered to be 
a favourable prognostic factor [2]. Anaemia is usually normocytic and 
normochromic [9]. 
Common neurological manifestations due to hypercalcemia include 
weakness, confusion and fatigue. Other manifestations include 
radiculopathy, loss of bowel or bladder control (due to involvement of the 
spinal cord) and carpal tunnel syndrome (due to infiltration of peripheral 
nerves by Amyloid). It may give rise to paraplegia in late stages. 
Patients with MM rarely live longer than 10 years [26]. A constellation 
of radiological, clinical, laboratory and pathological findings are combined 
to provide diagnostic criteria for plasma cell myeloma.   
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DIAGNOSTIC CRITERIA FOR MYELOMA [WHO 2001][27] 
A. The diagnosis of myeloma requires a minimum of one major and one 
minor criteria or three minor criteria which must include 1 & 2.These 
criteria must manifest in a symptomatic patient with progressive 
disease. 
B. MAJOR CRITERIA: 
Marrow plasmacytosis [ > 30 %] 
Plasmacytoma on biopsy 
M component [serum IgG >3.5gm / dl,IgA >3gm / dl, urine BJ 
protein > 1 gm / 24 hr] 
C. MINOR CRITERIA: 
Marrow plasmacytosis [10 – 30 %] 
M component present but less than above 
Lytic bone lesions 
Reduced nomal immunoglobulins - < 50 % normal. [ IgG < 600mg / 
dl, IgA <100mg / dl, IgM < 50 mg / dl] 
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DIAGNOSTIC CRITERIA FOR MYELOMA [ WHO 2004 ][28] 
SYMPTOMATIC PLASMA CELL MYELOMA 
§ M protein in serum or urine 
§ Bone marrow clonal plasma cells or plasmacytoma 
§ Related organ or tissue impairment 
ASYMPTOMATIC MYELOMA 
§ M protein in serum at myeloma levels [ 30gm / l] 
§ Clonal plasma cells in the bone marrow [ 10 % or more ] 
§ No related organ or tissue impairment 
NOTE 
§ No level of serum or urine M protein is included [M protein in most 
cases is IgG > 30 g/l, IgA > 25 g / l, urine light chain > 1 gm/ 24hr ]. 
But some patients with symptomatic myeloma have levels lower than 
these. 
§ Monoclonal plasma cells usually exceed 10% of nucleated cells in the 
marrow but no minimal level is designated. 5 % of patients with 
symptomatic myeloma have < 10 % marrow plasma cells 
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§ Manifestations of end organ damage include anaemia, hypercalcemia, 
lytic bone lesions, renal insufficiency, hyperviscosity, amyloidosis 
and recurrent infections. 
MYELOMA STAGING SYSTEM: SALMON AND DURIE’S 
CRITERIA 
STAGE I: 
§ Low M protein levels [IgG < 50 g / l, IgA < 30 g/ l, urine BJ < 4 gm / 
24 hrs] 
§ Absent or solitary bone lesion 
§ Normal Hb, serum Ca, Ig levels [non M protein ] 
STAGE II: 
§ Overall values between I and III 
STAGE III: 
§ High M protein levels [Ig G >70 g / l, IgA  > 50 g / l, urine BJ > 12 g 
/ 24 hrs] 
§ Advanced multiple lytic bone lesions 
§ Hb < 8.5g / dl, serum Ca > 12 mg /dl 
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SUBCLASSIFICATION: 
§ A – Serum creatinine <2 mg /dl 
§ B - Serum creatinine  >2 mg /dl  
INTERNATIONAL STAGING SYSTEM: 
STAGE I:  Serum beta 2 microglobulin < 3.5 mg / l 
               Serum albumin > 3.5 g / l 
STAGE II: Not stage I or III 
STAGE III: Serum beta 2 microglobulin > 5.5 mg / l 
BIOCHEMICAL FINDINGS 
The serum protein electrophoretic pattern shows a peak or localized 
band in 80% of patients. Bence Jones protein is found in the urine in 75 % 
of patients. Quantitative measurements of the paraprotein are necessary to 
establish a diagnosis and to monitor the disease. Additional findings include 
elevated serum calcium levels due to osteolysis and elevated serum 
creatinine levels due to reduced renal function. 
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RADIOGRAPHIC FINDINGS: 
The classic radiographic appearance of MM is that of multiple, well 
circumscribed, lytic, punched out, round lesions within the skull, spine and 
pelvis. Some patients may have diffuse osteopenia on radiography. Fewer 
than 10% of cases present with a single myelomatous lesion 
[plasmacytoma] which appear as bubbly expansions of a single bone, often 
the ribs or posterior elements of the spine. Radiographs of treated myeloma 
lesions may show areas of abnormal bone architecture with sclerosis. 
Around 79% of patients with myeloma demonstrate skeletal involvement.  
HEMATOLOGIC FINDINGS 
PERIPHERAL BLOOD 
Rouleaux formation is usually the most striking feature on peripheral 
blood smears. A leukoerythroblastic reaction is observed in some cases. 
Plasma cells are found on peripheral blood smears in approximately 15 % of 
cases, usually in small numbers. Marked plasmacytosis i.e. if the number of 
clonal plasma cells exceeds 2 x10(9) / l or 20% of the leukocyte differential 
count, accompanies plasma cell leukemia [28] . 
 
25 
 
BONE MARROW ASPIRATE 
Myeloma plasma cells vary from mature forms to immature, 
plasmablastic and pleomorphic forms. The mature forms are 
indistinguishable from normal / reactive plasma cells. They are usually oval 
with a round eccentric nucleus and spoke wheel or clock face chromatin 
without nucleoli. The plasmablastic cells contain a centrally placed large 
hyperchromatic or vesicular nuclei with one or more prominent nucleoli and 
scanty cytoplasm [29], [30]. Various unusual cytological appearances of plasma 
cells seen in BM aspirates include 
§ Flaming cells – deep magenta to pink staining in the peripheral part 
of the cytoplasm 
§ Mott, morula, grape cells – cells with multiple small globular 
cytoplasmic inclusions 
§ Thesaurocytes – plasma cells with abundant reticulated cytoplasm 
§ Russell bodies – large intracytoplasmic globules of proteins 
§ Dutcher bodies – pale Intranuclear inclusions 
These changes are not specific for myeloma since they may be found 
in reactive plasma cells. Other less known variants include cleaved cells, 
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pleomorphic variant, signet ring cells, histiocytoid cells, clear cells, spindle 
cells and oncocytic cells  
BONE MARROW TREPHINE BIOPSY: 
MM is a neoplasm of terminally differentiated B cells but its 
histological picture demonstrates the whole spectrum of B cell 
differentiation from small lymphocytes to plasma cells. The quantity of 
plasma cell burden in the biopsy proved to be useful criterion for histologic 
staging of multiple myeloma supplementing any clinical staging system in 
use. 
The plasma cells were dispersed in the marrow and were also seen in 
small clusters in the paratrabecular and perivascular regions. Usually the 
residual hematopoietic marrow was decreased with maturation inhibition of 
erythropoiesis and a corresponding increase in fat cells. Even in minimal 
infiltrations some nucleolated plasma cells were identified as a reliable 
diagnostic parameter in early cases of multiple myeloma. The percentage of 
plasma cells with prominent nucleoli correlated with the density and amount 
of plasma cell burden.  
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Bartl et al compared the cellular size, cytoplasmic structure and nuclear 
configuration and concluded that the spectrum of myeloma cells could be 
divided into six groups:[3],[31],[32] 
§ Marschalko 
§ Small cell  
§ Cleaved 
§ Polymorphous 
§ Asynchronous 
§ Blastic 
MARSCHALKO TYPE: 
These plasma cells are akin to normal mature plasma cells. They have 
an eccentric cart wheel nuclei, perinuclear hof and basophilic cytoplasm. 
Nucleoli were noted in some and mitotic figures were observed. Their main 
growth pattern was interstitial. 
SMALL CELL TYPE: 
These plasma cells are small and round with a mean size of 13 mic. 
The nucleus with its dense chromatin resembles that of a small lymphocyte 
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[lymphoplasmacytoid]. A narrow rim of basophilic cytoplasm having a 
perinuclear hoff is noted. Nucleoli and mitosis are rare. Interstitial growth 
pattern was the predominant growth pattern. 
CLEAVED TYPE: 
Most plasma cells have notched, cleaved or even convoluted nuclei of 
variable size with intranuclear inclusions. There is a low nucleocytoplasmic 
ratio with a small perinuclear hof. The marrow was frequently packed in this 
type together with a marked fibrosis. 
POLYMORPHOUS TYPE: 
The predominant features include marked cellular pleomorphism, 
multinuclearity and giant plasma cells. Many plasma cells have cytoplasmic 
inclusions. Nucleolus is mostly prominent and centrally located. No 
predominant proliferation pattern was noted. 
ASYNCHRONOUS TYPE: 
This type is characterized by a marked asynchronous maturation of 
nucleus and cytoplasm. These cells have a large eccentric nucleus with 
prominent nucleoli, abundant basophilic cytoplasm and pronounced 
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perinuclear hof. Marschalko cells, lymphocytes and immunoblasts are 
scattered among the asynchronous cells forming nodules. 
BLASTIC TYPE: 
The infiltration consists of plasmablasts with large nuclei, vey 
prominent centrally located nucleoli with a moderate rim of basophilic 
cytoplasm and a faint perinuclear hof. Complete replacement of the bone 
marrow is typical. 
PROGNOSTIC GRADING:  
When the clinical course and the survival of these six histologic subtypes 
were compared, three major prognostic groups emerged. 
§ MULTIPLE MYELOMA OF LOW GRADE MALIGNANCY 
Comprises the Marschalko and small cell types 
§ MULTIPLE MYELOMA OF INTERMEDIATE GRADE 
MALINANCY 
Consists of the cleaved, polymorphous and asynchronous cell types 
§ MULTIPLE MYELOMA OF HIGH GRADE MALIGNANCY 
It represents the plasmablastic type 
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HISTOLOGIC STAGING OF MULTIPLE MYELOMA:[33] 
Based on the plasma cell burden in the biopsy three stages are defined:  
STAGE I:    < 20% plasma cell mass 
                   80% hematopoietic and fat cells 
STAGE II:  20 – 50 % plasma cell mass 
                  Variable amount of hematopoiesis and fat cells 
STAGE III: > 50% plasma cell mass 
                   Residual marrow consisted mainly of fat cells 
HISTOLOGIC FACTORS PREDICTING UNFAVOUARABLE 
PROGNOSIS IN MYELOMA 
§ Nucleolated plasma cells 
§ Cleaved nuclei of plasma cells 
§ Large nuclei of plasma cells 
§ Mitotic figures of plasma cells 
§ Nodularity 
§ Packed marrow pattern 
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§ High tumour cell burden 
§ Low ratio of hematopoiesis / fatty tissue 
§ Coarse fibrosis 
§ High osteoclastic index 
IMMUNOPHENOTYPING 
Immunohistochemistry is often fraught with difficulties as both non 
neoplastic and neoplastic plasma cells express various hematopoietic and 
non hematopoietic antigens. 
Myeloma plasma cells usually express CD79a, CD 38, CD 138 and 
VS 38 C. In contrast to normal plasma cells, they are nearly always CD 19 
negative. CD 56 is aberrantly expressed in many cases.[34],[35] Aberrant 
expression of CD 117, CD 20, CD 52 and CD 10 may be seen. Some cases 
are cyclin D1 positive. 
Cytokeratin and epithelial membrane antigen positivity with 
leukocyte common antigen negativity could lead to an erroneous diagnosis 
of carcinoma.  
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DIAGNOSIS  
 Diagnosis is usually straight forward when the combination of diffuse 
osteoporotic or multiple osteolytic lesions, infiltration of the bone marrow 
with plasma cells and a serum or urine M protein is present [36] . 
§ Reactive plasmacytosis of the bone marrow can usually be 
distinguished from myeloma by the polyclonal nature of the serum Ig 
and absence of monoclonal Bence Jones protein in the urine 
§ Osteolytic lesions can also be caused by metastatic cancer. Presence 
of osteosclerosis tends to differentiate such lesions from myeloma 
§ Benign MGUS is very difficult to be differentiated from myeloma 
because the difference is essentially a quantitative rather than 
qualitative nature. Distinction can be made by less level of 
paraprotein, less degree of Ig suppression, lack of progression, lack 
of injurious clinical manifestations. 
TREATMENT 
  Although multiple myeloma is a well established clinical and 
immunological entity, progress in its treatment has been relatively slow. 
Partly it is due to difficulties associated with its biological behaviour. 
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Therapeutic interventions are required in patients with symptomatic and / or 
progressive myeloma. In general there are two sorts of therapy [37] . 
§ Systemic therapy to control the progression of myeloma 
§ Symptomatic supportive care to prevent serious morbidity 
Once a diagnosis of multiple myeloma has been made the initial standard 
treatment depends on whether the patient is a candidate for high dose 
chemotherapy with autologous stem cell transplant. 
Following drugs are to be used in a transplant candidate 
§ High dose pulsed glucocorticoids 
§ VAD chemotherapy [ vincristine 0.4 mg / d, doxorubicin 9mg/ m2/d, 
dexamethasone 40mg / day for 4 d / week ] 
§ Thalidomide [ 200 mg] + dexamethasone 40 mg for 4 days every 2 
weeks. 
In patients who are not transplant candidates, the therapy consisted of  
§ Intermittent pulses of an alkylating agent, L-phenyl alanine mustard [ 
LPAM melphalan] and prednisolone 
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Dose may need adjustments due to unpredictable absorption and differences 
in marrow tolerance. 
Relapsed myeloma can be treated with novel agents including lenolidomide 
and / or bortezomib. These agents target the tumour cells, tumour cell – 
bone marrow interaction and the bone marrow milieu. 
 
PROGNOSIS 
The outcome in an individual patient with myeloma is profoundly 
influenced by a number of factors. 
§ Patients presenting with stage I disease have a longer median survival 
than stage III disease 
§ Significant irreversible renal failure is associated with poor prognosis 
§ Patients with beneficial response to therapy have a better prognosis 
than those who are refractory 
§ The extent of tumour burden bears an inverse relationship to survival 
§ Progressive disease may be obvious from worsening clinical 
manifestations 
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Currently available chemotherapeutic agents tend to reduce the bulk 
of myeloma tissue and prolong the survival but virtually will never 
eliminate the disorder. 
The median overall survival of patients with myeloma is 7 – 8 years, 
with subsets of patients surviving over 10 years [38] . 
The major causes of death are progressive myeloma, renal failure, 
sepsis, therapy related acute leukemia or myelodysplasia. Nearly quarter of 
patients die of myocardial infarction, chronic lung disease, diabetes, stroke, 
all intercurrent illnesses related more to the age of the patient group than to 
the tumour. 
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 RESULTS AND ANALYSIS 
The total number of biopsies received during the study period was 25,084  
Total number of biopsies from the bone marrow: 976 
Total number of bone marrow aspirate samples: 1663 
Total number of cases diagnosed as multiple myeloma: 54 
 Of these 54 cases, only 34 patients underwent both bone marrow aspiration 
and biopsy procedure and they were included in the study.  The remaining 
20 cases for whom either aspirate sample or trephine biopsy were not done 
were excluded.  
AGE DISTRIBUTION: 
The mean age of the patients was 60 .6years (Range: 34 - 80 years) 
while all of them were more than 30 years  Thirteen patients (38.2%) were 
between the age of 61 and 70 years and 21  patients were between 51 and 70 
years. (Table 1)  Majority of the patients were males (22/34 cases) with the 
male to female ratio of 1.8:1.  
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TABLE 1:  AGE AND SEX DISTRIBUTION OF PATIENTS WITH MULTIPLE 
MYELOMA 
AGE (YEARS) NO. OF MALES (%) NO. OF FEMALES (%) 
31 - 40 2 (5.8) 0(0) 
41 - 50 2 (5.8) 2 (5.8) 
51 - 60 2 (5.8) 6 (17.6) 
61 - 70 11 (32.3) 2 (5.8) 
71 - 80 7 (20.5) 2 (5.8) 
TOTAL 22 12 
 
PERIPHERAL SMEAR FINDINGS IN PATIENTS WITH 
MULTIPLE MYELOMA: 
TABLE 2: MORPHOLOGICAL PICTURE IN THE PERIPHERAL SMEAR  
BLOOD PICTURE NO. OF PATIENTS 
NN (normocytic normochromic) 29 
MN (macrocytic normochromic) 5 
Total 34 
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As observed from table 2, NN picture was the most commonly 
observed peripheral smear pattern. Twenty patients showed exaggerated 
rouleaux formation in the peripheral smear and a bluish hue of the 
background was observed in 9 patients.  
HEMOGLOBIN LEVELS: Of the study group, hemoglobin levels were 
normal only in three patients while the remaining 31 cases were anemic 
[91.1 %]. The patients who had normal hemoglobin levels had a NN blood 
picture in the peripheral smear.  Four patients had hemoglobin levels less 
than 5 gm/dl (Table 3).   
TABLE 3: DISTRIBUTION OF CASES BASED ON HEMOGLOBIN LEVELS  
HB LEVEL NO. OF PATIENTS 
< 5 gm/dl 4 
5- 10 gm/dl 21 
10 – 12gm/dl 6 
>12 gm/dl 3 
Total 34 
 
Erythrocyte sedimentation rate (ESR) was elevated in all patients 
with 17 of them having a value of more than 100 mm/hr.  No significant 
39 
 
changes were observed in the morphological profile of leukocytes and 
platelets. Eight patients had leucopenia while three of them had 
leukocytosis. Thrombocytopenia was observed in 17 patients (50 %). 
Occasional plasma cells were observed in the peripheral smear of one 
patient. A plasma cell count of 57 % was observed in another patient for 
whom a diagnosis of plasma cell leukemia was made. 
TABLE 4: DISTRIBUTION OF CASES BASED ON % OF PLASMA CELLS  
Percentage of plasma cells in 
peripheral smear 
No. of patients 
0% 32 
1% 1 
57% 1 
 
Pancytopenia was observed in 5 patients, of which 2 patients each had 
MN anaemia and NN anaemia.The patient with plasma cell leukemia also 
presented with pancytopenia.  
 
 
40 
 
PATHOLOGICAL FINDINGS IN BONE MARROW ASPIRATE: 
Hypercellular bone marrow was observed in all patients. . The 
erythroid, myeloid series and megakaryocytes were relatively suppressed. 
The morphology and percentage of plasma cell infiltrate in the bone marrow 
are well established prognostic factors.  Plasma cell count of more than 50% 
was observed in twenty patients (Table 4).  
TABLE 5: PERCENTAGE OF PLASMA CELL INFILTRATE IN THE 
ASPIRATE SMEARS 
% OF PLASMA CELLS NO. OF PATIENTS FREQUENCY (%) 
30 - 40 10 29.4 
41 - 50 4 11.7 
51 - 60 4 11.7 
61 - 70 1 2.9 
71 - 80 5 14.7 
81 - 90 6 17.6 
91 - 100 4 11.7 
TOTAL 34  
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A mature plasma cell morphology was observed in 20 patients. These 
cells were spheroidal or ellipsoidal with eccentrically placed nucleus and 
abundant basophilic cytoplasm. The nuclear chromatin was dense with a 
perinuclear hof. Immature plasma cells with eccentrically placed relatively 
large nucleus, one or more nucleoli, diffuse chromatin pattern, a perinuclear 
clear zone and a variable amount of dense cytoplasm was observed in six 
patients. Plasma blasts with predominantly centrally placed large nucleus, 
round nucleoli and scant rim of cytoplasm were seen in eight cases. 
Few plasma cells in the bone marrow aspirates had a characteristic 
appearance. Mott cells (morular or grape cells) were seen in one patient, 
flame cells in one and pale intranuclear inclusions called dutcher bodies in 
one patient.  Binucleate and trinucleate plasma cells were observed  in 26 
cases (76.4%). 
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Fig 1 SUMMARIZES THE HEMOGLOBIN VALUES AND THE PLASMA CELL 
VOLUME IN THE BONE MARROW ASPIRATE    
 
 
 
 
 
PATHOLOGICAL FINDINGS IN BONE MARROW TREPHINE 
BIOPSY: 
Increased cellularity was observed in 32 patients while the remaining two 
had a normocellular marrow (Table 5). 
TABLE 6: ASSESSMENT OF CELLULARITY  
CELLULARITY  NO. OF PATIENTS  
Hypercellular  32 
Normocellular  2 
Hypocellular  0 
TOTAL 34 
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Complete marrow replacement was observed in 26 patients.  The 
plasma cells were dispersed in the marrow in four patients and a nodular 
infiltration in individual marrow spaces was seen in four patients (Table 6). 
The residual hematopoietic marrow was generally decreased (Table 7). 
TABLE 7: PATTERN OF INFILTRATION OF THE PLASMA CELLS 
PATTERN NO. OF PATIENTS 
Nodular  4 
Interstitial  4 
Mixed  0 
Diffuse  26 
TOTAL 34 
 
TABLE 8: IMPACT ON RESIDUAL HEMATOPOIESIS 
HEMATOPOIESIS NO. OF PATIENTS 
Increased 0 
Normal 2 
Suppressed 32 
TOTAL 34 
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Histologic staging of multiple myeloma was done based on the plasma cell 
burden in the biopsy as described by by Bartl et al (Table 8). 
TABLE 9: HISTOLOGIC STAGING OF MULTIPLE MYELOMA 
STAGE PLASMA CELL BURDEN NO. OF 
PATIENTS 
FREQUENCY 
I < 20 % 0 0 
II 20 – 50 % 8 23.5% 
III >50 % 26 76.4% 
 
As observed from the table, majority of the patients were in the stage 
III (26/34) at the time of diagnosis. 76.4% of the patients had more than 50 
% plasma cell infiltrate in the biopsy compared to only 58.6% in the aspirate 
indicating that the aspirate had underestimated the plasma cell burden. 
Fibrosis was not observed in any of the cases. 
  Histological grading of plasma cells was done based on Bartl’s 
criteria (Table 9). Marschalko’s types which are akin to normal plasma cells 
were the most commonly observed type.  Cleaved cell, polymorphous and 
asynchronous morphology were not visualized in any patient. 
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TABLE 10: HISTOLOGICAL GRADING OF PLASMA CELLS 
MORPHOLOGICAL 
SUBTYPE 
NO.OF 
PATIENTS 
FREQUENCY HISTOLOGICAL 
GRADE 
MARSCHALKO 22 64.7 low 
SMALL TYPE 4 11.7 low 
CLEAVED TYPE 0 0 Int 
POLYMORPHOUS 0 0 Int 
ASYNCHRONOUS 0 0 Int 
BLASTIC 8 23.5 High 
 
Analogous to the malignant lymphomas, Bartl et al has shown that 
multiple myeloma  can also be divided into  plasmacytic and plasmablastic 
morphology. For the purpose of analysis, well differentiated and 
intermediate type of myeloma cells were grouped together as plasmacytic 
type and poorly differentiated type of myeloma cells were taken as 
plasmablastic myeloma cells. 
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TABLE 11: COMPARISON OF TREPHINE BIOPSY FINDING 
WITH PLASMA CELL MORPHOLOGY 
PARAMETERS  PLASMACYTIC PLASMABLASTIC TOTAL 
VOLUME OF 
INFILTRATION 
< 20% 0 0 
34 20 – 50 % 8 0 
>50% 18 8 
PATTERN OF 
INFILTRATION 
INTERSTITIAL 2 2 
34 NODULAR 4 0 
DIFFUSE 20 6 
FIBROSIS PRESENT 0 0  
 
Plasmacytic morphology was present in 26 cases and plasmablastic 
morphology was observed in eight patients. Plasma cell infiltration of more 
than 50% was observed in all cases with plasmablastic morphology.   
Histologically unfavourable features (plasmablastic morphology, > 50% 
infiltration and diffuse pattern of infiltration) were observed in six patients. 
When a serum electrophoresis was performed, M band was demonstrated in 
88.2% of cases. 
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Elevated serum creatinine levels [2mg / dl] were noted in 12 / 34 cases 
FIG 2: DISTRIBUTION OF CASES BASED ON SERUM 
CREATININE LEVELS 
 
Larger percentage of cases [27 / 34 cases] had serum calcium levels less 
than 12 mg % 
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 DISCUSSION 
Multiple myeloma is a neoplastic disease of the bone marrow plasma 
cells causing lytic bone lesions, anaemia, renal insufficiency and 
hypercalcemia[39]. Despite the effectiveness of chemotherapy ,patients with 
multiple myeloma rarely live longer than 10 years. Kyle [1983] reported 
only 2 % of patients to survive for more than 10 years and Alexanian [1985] 
only 4% [40] . 
There have been very few studies from India [Carter et al, 1987, 
Terpstra et al 1992] which compared the value of bone marrow sections to 
smears. When a comparison was made between bone marrow aspirate and 
bone marrow biopsy procedures considerable discordance was observed in 
the volume of plasma cell infiltration in a high number of cases. The current 
study presents an approach to evaluate the bone marrow aspirate findings in 
multiple myeloma and to determine the value of bone marrow biopsy in 
establishing the diagnosis.  All patients had undergone a bone marrow 
aspiration and biopsy at the time of diagnosis. 
Our study showed a predominance of males with 22 /34 cases 
[64.7%] being men. Similar results were observed in previous studies [29][41]. 
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The mean age of the patients was 60.6 years which is consistent with that of 
western literature and studies conducted in India [41], [42]. 
In our study there were 31 patients [91.1%] with anaemia. In a study 
conducted by Bartl et al, anaemia was found in 68% of cases where as in 
that which was conducted by Singhal et al, 30.6% of cases had 
anaemia.Peripheral smear examination showed that the anaemia was 
normocytic normochromic in nature in majority of the patients [ 29 cases ]. 
In patients with multiple myeloma a dilutional effect of the expanded 
plasma volume with high concentrations of paraprotein contributes to 
lowered hemoglobin levels. Suppression of Erythropoiesis by bone marrow 
infiltration is an additional factor [43]. Other factors which contribute to 
anaemia are renal failure, chronic infection, bleeding and development of 
myelodysplastic or leukemic disorders. 
20 cases showed exaggerated rouleaux formation in the peripheral 
smear. Increased rouleaux formation is usually seen at high concentrations 
of serum immunoglobulins [44]. Blood grouping and cross matching may be 
difficult because of red cell rouleaux formation.ESR was found to be 
elevated in all the patients. 
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One of the patients was diagnosed with plasma cell leukemia with a plasma 
cell count of 57% in the peripheral smear. 
Leukocytopenia was observed in 8 patients and leucocytosis in 3 
patients. There were 17 patients with thrombocytopenia. Pancytopenia was 
noted in a proportion of patients [5 / 34 cases] 
It was observed in our study that those patients who had a 
hemoglobin level of < 5 gm % had greater than 80 % plasma cells on bone 
marrow aspirate smears. Studies by Subramanian et al have shown that 
hemoglobin levels correlate well with the percentage of plasma cells [2],[45]. 
In fact absence of anaemia was found to be a favourable prognostic factor. 
In our study we found that, hypercellular marrow was observed in all 
34 cases in the aspirate. 20 patients had a mature and 6 cases had a 
immature  plasma cell morphology. 8 patients had a plasmablastic 
morphology. Studies by Philip kuriakose et al have shown a relationship 
between plasma cell morphology and survival [30], [46], [47], [48], [49].  Thus, they 
concluded that plasma cell morphology which is considered as a significant 
prognostic factor in multiple myeloma should be incorporated in the already 
existing clinical system. 
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Although bone marrow examination is a traditional and a rapid 
method for quantification of plasma cells, it is subjected to variability. This 
is due to technical problems like blood dilution or sample clotting. 
Variabilty in sampling is also due to focal disease distribution [50].Thus the 
exact extent of marrow involvement is better appreciated on a biopsy. 
A histological classification and staging of myeloma based on bone 
marrow sections were proposed by Bartl and co workers. Important 
differences in survival were registered. But no comparison was made with 
the bone marrow smears. Very few studies compared the values of bone 
marrow sections to smears [51]. 
In the bone marrow trephine sections, the marrow was hypercellular 
in 32 patients. Usually the residual hematopoiesis was decreased. There 
were 32 patients with suppressed hematopoiesis. The normal hematopoietic 
reserve can be studied in bone marrow biopsy which is very essential for 
monitoring the therapy. 
Subramanian et al had found that 71 % of patients had > 50 % plasma 
cells in the infiltrate in the biopsy compared to only 40 % in the aspirate. In 
the present study we found that 76.4 % of patients had more than 50 % 
infiltrate in the biopsy compared to 58.6 % in the aspirate.ie the aspirate had 
53 
 
underestimated the plasma cell burden. Similar observations were made by 
Terpstra et al as well [51], [52]. 
The tumour cell load is frequently underestimated when only a bone 
marrow aspirate has been performed. This is probably due to a mesh of 
reticulin fibres around the plasma cells in larger groups, which makes 
plasma cells resistant to aspiration. Thus a biopsy seems to be a more 
sensitive parameter for assessing the plasma cell burden.  
Most cases of myelomas showed a diffuse pattern of infiltration in 
our study. [26/34 cases].In 4 patients each there was a nodular and 
interstitial pattern of infiltration. Interstitial pattern was the predominant 
pattern of infiltration in other studies [ sailer et al, pich et al and bartl et al]. 
According to Stifter S et al, the type of infiltration pattern was in 
proportion with the stage of the disease. Interstitial and nodular patterns 
were observed when the hematopoiesis was still preserved. In contrast 
diffuse pattern of infiltration results in suppression of hematopoiesis [53]. 
According to Sailer et al, of all the histologic parameters the degree 
ofplasma cell differentiation is the most important one [54]. There were 26 
cases with plasmacytic morphology and 6 cases with plasmablastic 
morphology. Studies by bartl et al and Subramanian et al  have shown  that 
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the plasma cell morphology has a good correlation  with volume of 
infiltration, pattern of infiltration and degree of fibrosis. But in our study 
although 6/8 cases [75%] showed a diffuse pattern of infiltration, similar 
frequency [76%] was also observed in patients with plasmablastic 
morphology [20 / 26 cases].  
The presence of fibrosis has been associated with a poor survival [54]. 
and it was not found in any of our cases. Fibrosis cannot be evaluated on 
aspirate smears. This again underlines the need to perform bone marrow 
biopsy in patients with multiple myeloma. 
In our series we had [22 / 34] 64.7 % of patients with Marschalko,                        
[4/ 34]11.75%  of  patients with small cell type and[ 8 / 34 ] 23.5 % of cases 
with blastic morphology. Recognition of morphological variants of plasma 
cells is necessary to avoid erroneous diagnosis. Presence of atypical forms 
should be reported in the pathological diagnosis because they are indicators 
of poor prognosis. 
Different series have quoted that all the above mentioned histological 
parameters  provide valuable prognostic information wherever other 
modalities like beta 2 microglobulin and IL6  are not available [33],[54]. 
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According to G. merlini et al and Bartl et al the four clinical factors of 
prognostic significance are Hb level, M component in serum, serum 
creatinine levels and serum calcium levels [55],[56]. 
In our study we noted that 91.1% of cases had anaemia, 88.2% of 
cases had M component in serum, 38.8 %of cases had elevated serum 
creatinine levels, and 26.4% had Hypercalcemia. James H Jandl has 
hypothesized that, when activated by myeloma cytokines, osteoclasts 
proliferate, cling to the surfaces of bone and cause osteolysis with release of 
calcium. The major causes of renal failure are myeloma kidney 
[precipitation of monoclonal light chains in distal and collecting tubules] 
and hypercalcemia. Other causes include dehydration, Hyperuricemia and 
amyloidosis [9]. 
Owing to the improvements in therapeutic procedures, the survival 
has significantly improved in the past 5 years for patients with myeloma [9]. 
These advances coupled with remarkable strides in the understanding of the 
biology of the disease provide considerable hope and optimism for both 
patients and myeloma researchers.  
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SUMMARY & CONCLUSIONS 
Of the 1663 bone marrow aspirates that we received during the study 
period, in our laboratory there were 54 cases of multiple myeloma. The 
median age for diagnosis was 60.6 years with a male predominance. The 
percentage of plasma cells in the BMA smears varied from 30-95%. 58.8% 
of cases had a mature plasma cell morphology. In the trephine biopsy, the 
predominate pattern of infiltration was the diffuse pattern [76.4%] and 
Marschalko’s type of plasma cells was the most commonly observed 
histological type [64.7%]. 23.5% of cases had a high grade malignancy as 
per Bartl’s criteria.   
Bone marrow examination is an essential investigation in the 
diagnosis of multiple myeloma. The plasma cell morphology at the time of 
diagnosis promises to be an important predictor of survival in patients with 
multiple myeloma. Therefore recognition of morphological variants of 
plasma cells is necessary to avoid erroneous diagnosis. Presence of atypical 
forms should be reported in the pathological diagnosis since they are 
indicators of poor prognosis. 
In many cases the diagnosis is obvious from the bone marrow aspirate 
alone. Bone marrow aspiration is a traditional and rapid method for 
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quantification and morphological assessment of plasma cells, but it is 
subjected to variability due to blood dilution, sample clotting and focal 
disease distribution. 
The factors which could be better judged in a trephine biopsy are, 
volume and pattern of infiltration which forms the basis for staging. 
Classification into low, intermediate and high grades based on histology, 
grading of fibrosis and plasma cell quantification by IHC are made possible 
in a trephine biopsy specimen. So, we recommend a bone marrow trephine 
biopsy in every case of suspected myeloma in addition to a bone marrow 
aspirate, because bone marrow trephine biopsy provides histologic 
parameters of prognostic significance. 
In conclusion, a combined evaluation of bone marrow aspirate and  
trephine biopsy is superior to achieve more accurate and informative data, 
because they are each independently diagnostic.  
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Hb 
BONE MARROW ASPIRATE 
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BONE MARROW TREPHINE 
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Rouleaux RBC WBC Platelet Hyper 
cellularity   
Plasma 
cell % 
Plasma Cell 
Morphology 
Hyper 
cellularity 
Pattern of 
infiltrate 
Histological 
grading 
Serum 
Creatinin
e 
Serum 
Calcium 
M 
band 
1.  Lakshmi  55/ 
F 
I05002076 + MN 7.7 1.5 6.5 + 32 M + Dif Mars 9.39 7.3 + 
2.  Kesavan  72/ 
M 
I05014587 + NN 7.2 2.3 8.3 + 86 PB + Int Blastic 0.7 8.5 + 
3.  Paramasivan  63/ 
M 
I05016401 _ NN 11.5 3.4 12.5 + 32 I N Int Mars 0.8 9.0 _ 
4.  Kamalaveni  58/ 
F 
I05022763 _ NN 4.6 2.4 10.7 + 90 PB + Dif Blastic  0.76 7.2 + 
5.  Palanisamy  73/ 
M 
I06008798 _ MN 1.3 0.90 10.0 + 30 M + Nod Mars 6.2 15.6 + 
6.  Thiruvengadam  66/ 
M 
I06034802 _ MN 14.7 1.6 9.3 + 33 M + Dif Small 1.3 9.1 + 
7.  Abdullakutty  61/ 
M 
I06019385 + MN 9.5 0.70 7.4 + 49 I + Dif  Mars 0.9 7.3 + 
8.  Vasudevan  71/ 
M 
I06023782 _ NN 4.9 2.75 11.1 + 55 PB + Dif Blastic 0.9 8.0 _ 
9.  Sivabagyam  67/ 
F 
I06027130 + NN 5.9 0.66 8.6 + 73 PB + Dif Blastic 0.7 10.4 + 
10.  Ramaswamy  69/ 
M 
I07003404 _ NN 7.0 2.4 12.5 + 50 I + Dif Mars 1.45 8.3 + 
11.  Arthanari  72/ 
M 
I07031341 + NN 8.2 2.11 6.7 + 67 PB + Dif Blastic 1.2 12.0 + 
12.  Palanisamy  70/M I07036414 _ NN 4.2 1.24 6.4 + 48 M + Nod Mars 8.4 8.7 + 
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13.  Bagavath singh  63/ 
M 
I08006790 + NN 2.5 7.1 7.6 + 38 M + Dif Mars 0.8 8.0 + 
14.  Seetha  50/ 
F 
I08007146 + MN 2.4 1.34 7.6 + 55 M + Dif Mars 7.88 7.3 + 
15.  Palanivel  70/ 
M 
I08008077 + NN 8.2 1.16 6.7 + 87 M + Dif Small 4.79 14.4 + 
16.  Nachammal  75 
/F 
I08020524 + NN 3.7 2.09 9.1 + 60 I + Dif Mars 0.89 10.4 + 
17.  Vijayalakshmi  53/ 
F 
I08029598 + NN 2.7 1.81 11.
3 
+ 32 M + Dif Small  0.98 8.36 + 
18.  Balu  63/ 
M 
I08032743 + NN 3.6 4.4 7.1 + 78 M + Dif Mars 1.3 9.2 + 
19.  Indrani  46/ 
F 
I08045107 + NN 6.2 1.35 4.2 + 93 M + Dif Small 7.47 9.55 + 
20.  Renganathan  45/ 
M 
I08045309 _ NN 5.2 7.6 4.7 + 92 M + Dif Mars 8.46 12.8 + 
21.  Jaishankar  33/ 
M 
I8048207 _ NN 7.0 1.22 6.1 + 94 M + Dif Mars 1.52 8.79 _ 
22.  Raju  60/ 
M 
I09045617 + NN 7.9 1.90 9.3 + 75 I + Dif Mars 0.95 9.0 + 
23.  Pushpa Rengaraju  51/ 
F 
I09026686 + NN 7.9 1.75 9.8 + 95 PB + Int Blastic 0.99 8.5 + 
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24.  Jai Shankar  34/ 
M 
I09042191 + NN 6.2 1.16 9.1 + 82 M + Dif Mars 2.3 8.15 + 
25.  Abdul azeez  65/ 
M 
I09041721 + NN 11.6 0.95 7.7 + 50 PB + Dif Blast 3.5 9.21 + 
26.  Palanisamy  65/ 
M 
I09044453 + NN 5.5 1.52 9.9 + 55 M + Dif Mars 0.94 7.2 + 
27.  Muthammal  52/ 
F 
I10013224 + NN 3.2 1.87 8.0 + 40 M + Dif Mars 0.7 9.1 + 
28.  Ganesamoorthy  65/ 
M 
I10018691 _ NN 5.9 2.2 5.7 + 32 M + Nod Mars 8.2 12.3 + 
29.  Govindammal  75/ 
F 
I10034240 _ NN 14.9 1.27 9.9 + 35 M N Int Mars 1.2 7.2 + 
30.  Balan  48/ 
M 
I10037556 _ NN 7.1 1.60 13.
9 
+ 40 M + Nod Mars 1.29 8.36 + 
31.  Ramasamy  57/ 
M 
I11014588 _ NN 14.9 3.65 11.
5 
+ 85 M + Dif Mars 0.76 9.1 + 
32.  Dhanalakshmi  58/ 
F 
I11015386 + NN 4.7 0.92 11.
0 
+ 80 I + Dif Mars 1.45 15.6 + 
33.  Duraisamy  74/ 
M 
I11018831 _ NN 2.2 1.18 4.2 + 80 M + Dif Mars 9.39 12.0 _ 
34.  Deivanayaki  64/ 
F 
I11029029 + NN 9.0 0.36 4.8 + 85 PB + Dif Blastic 2.74 7.5 + 
KEY TO MASTER CHART  
 
§ NN  - NORMOCYTIC NORMOCHROMIC 
§ MN  - MACROCYTIC  NORMOCHROMIC 
§ M  - MATURE  
§ I  - IMMATURE  
§ PB  - PLASMABLASTIC  
§ Dif  - DIFFUSE  
§ Nod  - NODULAR  
§ Int  - INTERSTITIAL 
§ Mars  - MARSCHALKO  
    
  
   
